Company Overview
About InterVenn Biosciences
InterVenn Biosciences is a clinical-stage diagnostics company that has pioneered the field of glycoproteomics — the study of proteins modified with sugar molecules (glycans) — combined with artificial intelligence to develop next-generation liquid biopsy tests for cancer detection and treatment monitoring. The company's VOCAL test provides a non-invasive diagnostic for ovarian cancer using a blood draw, and its GlycoKnowPR platform delivers glycoproteomic immunotherapy response assays to help oncologists predict how patients will respond to treatment before administering therapy.
Business Model & Competitive Advantage
Founded in 2017 and headquartered in South San Francisco, InterVenn has raised $251M across six funding rounds, with the most significant being a $201M Series C in 2021. The company achieved a milestone in July 2025 when VOCAL received an AMA PLA code, a key step toward insurance coverage and clinical reimbursement that enables broader commercial adoption. In January 2026, InterVenn partnered with Aranscia to accelerate commercialization of GlycoKnowPR, extending its reach into the immuno-oncology testing market.
Competitive Landscape 2025–2026
InterVenn's glycoproteomics platform represents a differentiated approach in an increasingly competitive liquid biopsy market dominated by companies like Guardant Health and Grail that focus on cell-free DNA (cfDNA). By analyzing the glycan layer of proteins — which is altered in cancer states — InterVenn targets orthogonal biomarker signals that may provide earlier and more specific disease detection, particularly in cancers like ovarian cancer where early diagnosis dramatically improves outcomes.
Key Differentiators
Emerging Innovator
InterVenn Biosciences is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare InterVenn Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from InterVenn Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim InterVenn Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention InterVenn Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →